Atrial fibrillation (AF) is prevalent in a large proportion of patients with sick sinus syndrome (SSS) and is associated with an increased risk of thromboembolism. DANPACE II is a Danish multicentre randomised controlled trial (N=540) investigating whether reducing pacing rate to 40 bpm with the rate-response function off reduces the incidence of AF compared to conventional pacemaker programming at a lower pacing rate of 60 bpm and activated rate-response function in patients with SSS.
Clinicaltrials.gov identifier: NCT02034526
Leadless vs. RV pacing
This study investigates standard transvenous dual chamber pacing (DDD) vs. leadless AV synchronous pacing (VDD) vs. single chamber rate responsive pacing (VVIR) in patients with persistent AV-block. The main aim is to compare quality of life, exercise capacity, and safety of leadless AV synchronous VDD pacing using the Micra PM with traditional transvenous AV synchronous dual chamber DDD pacing in patients with persistent AV-block.
ARTESiA – Apixaban for the Reduction of Thrombo-Embolism in patients with device-detected Sub-clinical Atrial fibrillation (SCAF)
A 4000-patient international randomized controlled trial investigating the efficacy of oral anticoagulation in patients with CIED and subclinical short episodes of device-detected SCAF. The main goal is to determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin. AUH is national coordinating centre for ARTESiA. Clinicaltrials.gov identifier: NCT01938248. collaboration with Jeff Healey, Population Health Research Institute (PHRI), Hamilton, Canada.